Featuring the use of FAIR data principles for COVID-19 research, the recently published Hong Kong Principles, an update to the Declaration to Improve Biomedical & Health Research, a call to support universities with their open data, a collation of preprint review services, an assessment of clinical journals’ attitudes towards preprints and a case study outlining … Continue reading Weekly digest: what’s happening in open science?
Blog
Weekly digest: what’s happening in open science?
Featuring the ERC’s decision to split from Plan S, a report on the Open Pharma June 2020 virtual roundtable meeting in BMJ Opinion, solutions for improving transparency, the Data Ethics Canvas tool, Beck et al.’s recommendations for preprint server best practice, a concerning increase in citation rates for journals discontinued from the Scopus database and … Continue reading Weekly digest: what’s happening in open science?
Weekly digest: what’s happening in open science?
Featuring the new cOAlition S Rights Retention Strategy, an analysis of institutional open access output, subjectivity in peer review reports, insights on opening up science to the public, appeals against Clarivate’s blacklist decision and concerns of questionable editorial practices. The new Rights Retention Strategy via cOAlition S To ensure the compliance of exclusive publishing agreements … Continue reading Weekly digest: what’s happening in open science?
Weekly digest: what’s happening in open science?
Featuring the grey area surrounding predatory journals, a breakdown of APC price increases, The Company of Biologists’ decision to freeze fees, the Metadata 2020 Principles, how researchers feel about data sharing technologies and the University of Cambridge’s response to UKRI Open Access Review consultation. Defining predatory journals via The Publication Plan The line between predatory … Continue reading Weekly digest: what’s happening in open science?
Evidence-based medicine no more?
In a pre-COVID-19 world, this week would have seen evidence-based medicine experts gather in Toronto for EBM Live 2020. However, like many other meetings during the pandemic, it has been postponed. Here, I reflect on last year’s meeting and pharma’s journey in improving the reporting of clinical trials.
Weekly digest: what’s happening in open science?
Featuring the evolving landscape of scientific publishing in the wake of COVID-19, the new journal dedicated to COVID-19 research, best practice for social media communication in the medical community, the Department for Business, Energy & Industrial Strategy’s R&D roadmap, a ‘How To’ guide for patient engagement and case studies in open science. Change is coming … Continue reading Weekly digest: what’s happening in open science?
Reproducible research and industry partnership jointly generate high-impact scientific discoveries
The hallmarks of sound science are reproducibility and generalizability that have been subjected to scientific peer review. If any of these characteristics is missing, science is lost. It sounds very simple, but anomalies and deficiencies are everywhere.
Weekly digest: what’s happening in open science?
Featuring the FDA’s Project Patient Voice, certification for ORCID service providers, a call for responsible reporting of COVID-19 mathematical models, an analysis of open peer review journals, how the ABPI will navigate Brexit and the changing landscape of research communication. Introducing Project Patient Voice via Bloomberg Law Project Patient Voice is a pilot initiative from … Continue reading Weekly digest: what’s happening in open science?
Ways to increase transparency, trust and patient involvement in pharma-funded publications – insights from the virtual 16th Annual Meeting of ISMPP
This year, the Annual Meeting of the International Society for Medical Publication Professionals (ISMPP) went virtual. With a mix of engaging live and recorded sessions, 15 roundtables and over 45 posters to delve into, we share some of the highlights from the meeting.
“Pharma are doing ok in terms of open access, but they could be doing more” – insights from the Open Pharma June roundtable meeting
Open Pharma Members, Supporters and key Advisers came together to discuss the ways in which the scientific publishing community can make research accessible, discoverable and transparent for patients and the public.